1 | **Comment**- IMP inhalation solution identical to ventavis inhalation solution, but IMP is in a different volume presentation. Please see covering letter. | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 💬 |
2 | 1 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
3 | 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
4 | 10% Metronidazole Ointment (METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Metronidazole Topical Gel) | 1件: Metronidazole
Metronidazole
(METRONIDAZOLE TOPICAL CREAM) 💬 | - | - | 1件: 96 96 💬 |
5 | 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
6 | 15N2-tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
7 | 3 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
8 | 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
9 | 7 mg QD to 15 mg QD PF-06649751 | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
10 | 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) | 1件: Tavapadon Tavapadon | 1件: Tavapadon
Tavapadon
💬 | 2件: DRD1 DRD1, DRD5 💬 | 10件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
11 | Abatacept, rituximab or tocilizumab | 3件: Abatacept Abatacept, Rituximab, Tocilizumab | 3件: Tocilizumab
Tocilizumab
,
Rituximab
,
Abatacept
💬 | 4件: CD80 CD80, CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
12 | ABP 710 - Biosimilar to infliximab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
13 | ABP 798 - Biosimilar to rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
14 | ABP 798 Biosimilar to Rituximab | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
15 | ABP 959 - biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
16 | ABP 959 - proposed biosimilar to eculizumab | 1件: Eculizumab Eculizumab | 1件: Eculizumab
Eculizumab
💬 | 1件: C5 C5 💬 | 11件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Regulation of actin cytoskeleton, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 💬 |
17 | AC-203 1% Topical Ointment | - | - | - | - | 1件: 162 162 💬 |
18 | Active topical NS2 1% dermatologic cream | - | - | - | - | 1件: 160 160 💬 |
19 | Adalimuab, Etanercept, Tocilizumab, or Abatacept | 3件: Abatacept Abatacept, Etanercept, Tocilizumab | 3件: Etanercept
Etanercept
,
Tocilizumab
,
Abatacept
💬 | 5件: CD80 CD80, CD86, IL6R, LTA, TNF 💬 | 80件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
20 | Adalimumab (up to 9 months exposure) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
21 | ADENO-ASSOCIATED VIRUS SEROTYPE 5 ENCODING A MICRORNA TARGETED TO HUMAN HUNTINGTIN GENE | - | - | - | - | 1件: 8 8 💬 |
22 | ADX-102 1% Topical Dermal Cream (reproxalap) | 1件: Reproxalap Reproxalap | 1件: Reproxalap
Reproxalap
💬 | - | - | 1件: 160 160 💬 |
23 | Alpha-tocopherol | 2件: Tocopherol Tocopherol, Vitamin E (alpha-tocopherol) | 2件: Vitamin E
Vitamin E
,
Tocopherol
💬 | - | - | 2件: 49 49, 206 💬 |
24 | Alpha-tocotrienol quinone | 1件: Tocotrienol Tocotrienol | - | - | - | 2件: 21 21, 156 💬 |
25 | Alpha-tocotrienolquinone | - | - | - | - | 1件: 18 18 💬 |
26 | Also referred to as 'MEDI2070' | - | - | - | - | 2件: 96 96, 97 💬 |
27 | Also referred to as MED2070 | - | - | - | - | 1件: 96 96 💬 |
28 | Also referred to as MEDI2070 | - | - | - | - | 2件: 96 96, 97 💬 |
29 | Alvelestat tosylate | 1件: Alvelestat Alvelestat | - | - | - | 1件: 231 231 💬 |
30 | Amoxicillin, metronidazole and doxycycline (METRONIDAZOLE TOPICAL CREAM) | 3件: Amoxicillin Amoxicillin, Doxycycline, Metronidazole (Metronidazole Topical Gel) | 5件: Amoxicillin
Amoxicillin
,
Doxycycline
,
Metronidazole
(METRONIDAZOLE TOPICAL CREAM),
Amoxicillin
,
Doxycycline
💬 | - | - | 1件: 97 97 💬 |
31 | AndroGel 1 % Topical Gel | - | - | - | - | 1件: 13 13 💬 |
32 | Anesthetic Topical Adhesive Synera | - | - | - | - | 1件: 13 13 💬 |
33 | Antiepileptic drug (1 to 3 only) | - | - | - | - | 1件: 158 158 💬 |
34 | Apitox - pure honeybee toxin | - | - | - | - | 1件: 13 13 💬 |
35 | Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E) | 3件: Ascorbic acid Ascorbic acid (Tobakient), Tocopherol, Vitamin E (alpha-tocopherol) | 3件: Ascorbic acid
Ascorbic acid
,
Vitamin E
,
Tocopherol
💬 | - | - | 1件: 206 206 💬 |
36 | Atomoxetine (Tomoxetine) | 1件: Atomoxetine Atomoxetine (Tomoxetine) | 1件: Atomoxetine
Atomoxetine
(Tomoxetine) 💬 | 1件: SLC6A2 SLC6A2 💬 | 1件: Synaptic vesicle cycle Synaptic vesicle cycle 💬 | 4件: 6 6, 8, 13, 17 💬 |
37 | Autologous mature tolerogenic monocyte-derived Dendritic Cells loaded with the B29 peptide of HSP70 | - | - | - | - | 1件: 46 46 💬 |
38 | Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
39 | Avonex and Topamax | 1件: Interferon beta-1a Interferon beta-1a | 1件: Interferon beta-1a
Interferon beta-1a
💬 | 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 💬 |
40 | Azithromycin + Metronidazole (METRONIDAZOLE TOPICAL CREAM) | 2件: Azithromycin Azithromycin, Metronidazole (Metronidazole Topical Gel) | 3件: Metronidazole
Metronidazole
(METRONIDAZOLE TOPICAL CREAM),
Azithromycin
,
Azithromycin
💬 | - | - | 1件: 96 96 💬 |
41 | BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) | 5件: Abatacept Abatacept, Adalimumab, Etanercept, Golimumab, Infliximab | 5件: Etanercept
Etanercept
,
Adalimumab
,
Infliximab
,
Abatacept
,
Golimumab
💬 | 4件: CD80 CD80, CD86, LTA, TNF 💬 | 74件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
42 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 2件: Bezafibrate Bezafibrate, Ursodeoxycholic acid (BAMBOO SALT Eunganggo Jook Yeom Toothpaste) | 2件: Ursodiol
Ursodiol
,
Bezafibrate
💬 | 2件: NR1H4 NR1H4, PPARA 💬 | 11件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Bile secretion, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 💬 |
43 | BIIB067 (Tofersen) | 1件: Tofersen Tofersen | 1件: Tofersen
Tofersen
💬 | 1件: SOD1 SOD1 💬 | 8件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Chemical carcinogenesis - reactive oxygen species, Huntington disease, Longevity regulating pathway - multiple species, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Peroxisome, Prion disease 💬 | 1件: 2 2 💬 |
44 | Biological: Benralizumab, Biological: Placebo to Mepolizumab | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: Mepolizumab
Mepolizumab
,
Benralizumab
💬 | 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 💬 |
45 | Biological: Mepolizumab, Biological: Placebo to Benralizumab | 2件: Benralizumab Benralizumab, Mepolizumab | 2件: Mepolizumab
Mepolizumab
,
Benralizumab
💬 | 2件: IL5 IL5, IL5RA 💬 | 13件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation 💬 | 1件: 44 44 💬 |
46 | Biosimilar product to adalimumab | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
47 | Bony Toxicity | - | - | - | - | 1件: 34 34 💬 |
48 | Bortezomib D-mannitol (Tobrex (TN)) | 3件: Bortezomib Bortezomib, Bortezomib D-mannitol, Mannitol | 2件: Mannitol
Mannitol
(Tobrex (TN)),
Bortezomib
💬 | 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 1件: 28 28 💬 |
49 | Botulinic toxin | - | - | - | - | 1件: 36 36 💬 |
50 | Botulinum A toxin | - | - | - | - | 1件: 118 118 💬 |
51 | Botulinum Toxin | - | - | - | - | 3件: 6 6, 13, 149 💬 |
52 | Botulinum toxin A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 4件: 13 13, 51, 149, 226 💬 |
53 | BOTULINUM TOXIN A - HAEMAGGLUTININ COMPLEX | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
54 | BOTULINUM TOXIN TYPE A | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 10件: 2 2, 5, 6, 7, 13, 15, 17, 70, 113, 149 💬 |
55 | Botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 70 70 💬 |
56 | Botulinum Toxin Type A 200U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
57 | Botulinum Toxin Type A 300U | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
58 | Botulinum toxin type B | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: Rimabotulinumtoxin B
Rimabotulinumtoxin B
(Botulinum toxin type B (JAN)) 💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 3件: 2 2, 6, 51 💬 |
59 | Botulinum toxin type B (2500 units / vial) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: Rimabotulinumtoxin B
Rimabotulinumtoxin B
(Botulinum toxin type B (JAN)) 💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 💬 |
60 | Botulinum toxin type B (Myobloc) | 1件: Botulinum toxin type B Botulinum toxin type B | 1件: Rimabotulinumtoxin B
Rimabotulinumtoxin B
(Botulinum toxin type B (JAN)) 💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 2件: 2 2, 6 💬 |
61 | Botulinum toxin(Botox) | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 51 51 💬 |
62 | Botulinum Toxin: Xeomin | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 6 6 💬 |
63 | Botulism Toxin Treatment | - | - | - | - | 1件: 161 161 💬 |
64 | C-82 Topical Gel, 1% | - | - | - | - | 1件: 51 51 💬 |
65 | C-type natriuretic peptide conjugated to a multi-arm polyethylene glycol carrier molecule through a cleavable linker | 1件: Polyethylene glycol Polyethylene glycol (Topcare ClearLax) | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
66 | C-TYPE NATRIURETIC PEPTIDE CONJUGATED TO MULTI-ARM POLYETHYLENE GLYCOL CARRIER THROUGH A CLEAVABLE LINKER | 1件: Polyethylene glycol Polyethylene glycol (Topcare ClearLax) | 1件: Polyethylene glycol 3350
Polyethylene glycol 3350
💬 | - | - | 1件: 276 276 💬 |
67 | Ceftazidime and tobramycin | 2件: Ceftazidime Ceftazidime, Tobramycin | 3件: Tobramycin
Tobramycin
,
Ceftazidime
,
Ceftazidime
💬 | - | - | 1件: 299 299 💬 |
68 | Chong Kun Dang Tofacitinib Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
69 | Cistanche Total Glycosides | - | - | - | - | 1件: 2 2 💬 |
70 | Clobetasol 0.05% Topical Ointment | 1件: Clobetasol Clobetasol | 1件: Clobetasol
Clobetasol
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 162 162 💬 |
71 | CLOSTRIDIUM BOTULINUM TOXIN TYPE A | 2件: Botulinum toxin type A Botulinum toxin type A, Clostridium botulinum | 1件: Botulinum toxin type A
Botulinum toxin type A
💬 | 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 1件: 13 13 💬 |
72 | Cohort 1: hATG, CsA, EPAG Day 14 to Month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
73 | Cohort 2: hATG, CsA, EPAG Day 14 to Month 3 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
74 | Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1) | 1件: Nilotinib Nilotinib | 1件: Nilotinib
Nilotinib
💬 | 4件: ABL1 ABL1, KIT, PDGFRA, PDGFRB 💬 | 33件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 6 6 💬 |
75 | Cohort 3: hATG, CsA (dose reduced), EPAG day 1 to month 6 | 1件: Antilymphocyte immunoglobulin (horse) Antilymphocyte immunoglobulin (horse) | - | - | - | 1件: 60 60 💬 |
76 | Combination Product: Beclomethasone dipropionate in addition to MC-EVOO | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: Beclomethasone dipropionate
Beclomethasone dipropionate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
77 | Combination Product: Beclomethasone dipropionate in addition to refined oil | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 1件: Beclomethasone dipropionate
Beclomethasone dipropionate
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
78 | Corticoids+ tocilizumab 8mg/Kg/4 weeks | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
79 | Cotoretigene Toliparvovec | 1件: Cotoretigene toliparvovec Cotoretigene toliparvovec | - | - | - | 1件: 90 90 💬 |
80 | CP-690,550 (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 107 💬 |
81 | CT-P47 AI (tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
82 | CT-P47 PFS (tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
83 | Cystic Fibrosis Ready to Use Supplemental Food | - | - | - | - | 1件: 299 299 💬 |
84 | D-a-tocopheryl PEG 1000 succinate | - | - | - | - | 1件: 299 299 💬 |
85 | Decrease Tocilizumab, Abatacept | 2件: Abatacept Abatacept, Tocilizumab | 2件: Tocilizumab
Tocilizumab
,
Abatacept
💬 | 3件: CD80 CD80, CD86, IL6R 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
86 | Denosumab - - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
87 | Denosumab - Immunoglobulin G2 Human Monoclonal Antibody to RANK Ligand | 1件: Denosumab Denosumab | 1件: Denosumab
Denosumab
💬 | 1件: TNFSF11 TNFSF11 💬 | 8件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Osteoclast differentiation, Parathyroid hormone synthesis, secretion and action, Prolactin signaling pathway, Rheumatoid arthritis 💬 | 1件: 274 274 💬 |
88 | Diclofenac sodium topical gel | 1件: Diclofenac Diclofenac (Diclofenac Sodium Topical Solution) | 1件: Diclofenac
Diclofenac
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 13 13 💬 |
89 | Diphtheria toxoid | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 13 13, 46 💬 |
90 | DP Mannitol (Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
(Tobrex (TN)) 💬 | - | - | 1件: 299 299 💬 |
91 | Dry powder tobramycin | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
92 | EGCG + Tocotrienol | 2件: Epigallocatechin gallate Epigallocatechin gallate, Tocotrienol | - | - | - | 1件: 299 299 💬 |
93 | Essential amino acid intake + Leucine vs total AA supplement | 1件: Leucine Leucine | 1件: Leucine
Leucine
💬 | - | - | 1件: 299 299 💬 |
94 | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab | 4件: Abatacept Abatacept, Rituximab, Sarilumab, Tocilizumab | 4件: Tocilizumab
Tocilizumab
,
Rituximab
,
Abatacept
,
Sarilumab
💬 | 4件: CD80 CD80, CD86, IL6R, MS4A1 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
95 | Exposure to golimumab | 1件: Golimumab Golimumab | 1件: Golimumab
Golimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 💬 |
96 | Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS | - | - | - | - | 1件: 13 13 💬 |
97 | Fluocinolone Acetonide (FLUOCINOLONE ACETONIDE TOPICAL) | 2件: Fluocinolone Fluocinolone, Fluocinolone acetonide (Fluocinolone Acetonide Topical) | 1件: Fluocinolone acetonide
Fluocinolone acetonide
(FLUOCINOLONE ACETONIDE TOPICAL) 💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 90 90 💬 |
98 | Furosemide (14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) | 1件: Furosemide Furosemide (14-Panel Toxicology Medicated Collection System) | 1件: Furosemide
Furosemide
(14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) 💬 | 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 2件: 6 6, 86 💬 |
99 | Furosemide Injection (14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) | 1件: Furosemide Furosemide (14-Panel Toxicology Medicated Collection System) | 1件: Furosemide
Furosemide
(14-PANEL TOXICOLOGY MEDICATED COLLECTION SYSTEM) 💬 | 1件: SLC12A2 SLC12A2 💬 | 3件: Pancreatic secretion Pancreatic secretion, Salivary secretion, Vibrio cholerae infection 💬 | 1件: 6 6 💬 |
100 | Gamma-Tocopherol | 2件: Tocopherol Tocopherol, gamma-Tocopherol | 1件: Tocopherol
Tocopherol
💬 | - | - | 1件: 13 13 💬 |
101 | GM-CSF, fosfomycin and metronidazole (METRONIDAZOLE TOPICAL CREAM) | 2件: Fosfomycin Fosfomycin, Metronidazole (Metronidazole Topical Gel) | 2件: Metronidazole
Metronidazole
(METRONIDAZOLE TOPICAL CREAM),
Fosfomycin
💬 | - | - | 1件: 97 97 💬 |
102 | HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 2件: 13 13, 14 💬 |
103 | HOV-12020 (Palm tocotrienols complex) | - | - | - | - | 1件: 124 124 💬 |
104 | Human Monoclonal Antibody (CNTO 1275) to Interleukin 12p-40 | - | - | - | - | 1件: 96 96 💬 |
105 | Human monoclonal antibody (CNTO 1275) to interleukin-12p40 | - | - | - | - | 1件: 13 13 💬 |
106 | HUMAN SERUM ALBUMIN (HSA) FUSED TO RECOMBINANT HUMAN GROWTH HORMONE (HGH) | 2件: Albumin human Albumin human, Somatotropin | 1件: Albumin human
Albumin human
💬 | - | - | 1件: 78 78 💬 |
107 | Human Serum Albumin (HSA) fused to somatropin | 2件: Albumin human Albumin human, Somatotropin | 1件: Albumin human
Albumin human
💬 | - | - | 1件: 78 78 💬 |
108 | IDPM: Inhaled Dry Powder Mannitol (Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
(Tobrex (TN)) 💬 | - | - | 1件: 299 299 💬 |
109 | IDURONATE-2-SULFATASE FUSED TO A FC POLYPEPTIDE THAT BINDS TO THE HUMAN TRANSFERRIN RECEPTOR | - | - | - | - | 1件: 19 19 💬 |
110 | Iloprost therapy up to 2 ng/kg x min | 1件: Iloprost Iloprost | 1件: Iloprost
Iloprost
💬 | 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 51 51 💬 |
111 | In double-blind phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 💬 |
112 | In open-label phase: treatment with tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 107 107 💬 |
113 | Incobotulinum Toxin A | - | - | - | - | 3件: 2 2, 6, 13 💬 |
114 | Inhaled Dry Powder Mannitol (Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
(Tobrex (TN)) 💬 | - | - | 1件: 299 299 💬 |
115 | Inhaled Mannitol (Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
(Tobrex (TN)) 💬 | - | - | 1件: 299 299 💬 |
116 | Inhaled tobramycin | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
117 | INN-Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 266 266 💬 |
118 | Insulin glargine (TOUJEO) | 1件: Insulin glargine Insulin glargine (Toujeo) | 1件: Insulin glargine
Insulin glargine
(TOUJEO) 💬 | 1件: INSR INSR 💬 | 22件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Diabetic cardiomyopathy, FoxO signaling pathway, HIF-1 signaling pathway, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Non-alcoholic fatty liver disease, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Phospholipase D signaling pathway, Rap1 signaling pathway, Ras signaling pathway, Regulation of lipolysis in adipocytes, Type II diabetes mellitus, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 299 299 💬 |
119 | Interferon beta treatment to add-on atorvastatin treatment | 2件: Atorvastatin Atorvastatin, Human interferon beta | 1件: Atorvastatin
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
120 | Intra-articular Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
121 | Intradetrusor injection of Botulinum Toxin-A | - | - | - | - | 1件: 13 13 💬 |
122 | Intravenous (i.v.) methylprednisolone 1000 mg, total 9 | 1件: Methylprednisolone Methylprednisolone | 1件: Methylprednisolone
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 222 222 💬 |
123 | Intravesical injection of Botulinum A toxin | - | - | - | - | 2件: 6 6, 17 💬 |
124 | IPD® (suplatast tosilate) | - | - | - | - | 1件: 226 226 💬 |
125 | Itraconazole (TOLSURA) | 1件: Itraconazole Itraconazole (Tolsura) | 1件: Itraconazole
Itraconazole
(TOLSURA) 💬 | - | - | 6件: 3 3, 46, 65, 96, 227, 299 💬 |
126 | Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally. (TOLSURA) | 2件: Itraconazole Itraconazole (Tolsura), Terbinafine (Terbinafine HCl Chlortimazole and Tolnaftate) | 2件: Itraconazole
Itraconazole
(TOLSURA),
Terbinafine
💬 | - | - | 1件: 96 96 💬 |
127 | Itraconazole/voriconazole (TOLSURA) | 2件: Itraconazole Itraconazole (Tolsura), Voriconazole | 2件: Itraconazole
Itraconazole
(TOLSURA),
Voriconazole
💬 | - | - | 1件: 299 299 💬 |
128 | Itraconazole? SHR0302 tablets (TOLSURA) | 1件: Itraconazole Itraconazole (Tolsura) | 1件: Itraconazole
Itraconazole
(TOLSURA) 💬 | - | - | 1件: 46 46 💬 |
129 | IV tobramycin | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
130 | Jinarc - Tolvaptan tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
131 | Ketorolac (Toradol (TN)) | 1件: Ketorolac Ketorolac (Toradol) | 1件: Ketorolac
Ketorolac
(Toradol (TN)) 💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 2件: 70 70, 226 💬 |
132 | Ketorolac Tromethamine (Toradol (TN)) | 2件: Ketorolac Ketorolac (Toradol), Tromethamine | 2件: Tromethamine
Tromethamine
,
Ketorolac
(Toradol (TN)) 💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 226 226 💬 |
133 | Lentivirus-mediated delivery of ARSA to the CNS. | - | - | - | - | 1件: 19 19 💬 |
134 | Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field | - | - | - | - | 1件: 13 13 💬 |
135 | LMX 4 Topical Cream | - | - | - | - | 1件: 256 256 💬 |
136 | MabionCD20 (candidate biosimilar to rituximab) | 1件: Rituximab Rituximab | 1件: Rituximab
Rituximab
💬 | 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 💬 |
137 | Mannitol (Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
(Tobrex (TN)) 💬 | - | - | 7件: 6 6, 13, 28, 60, 96, 113, 299 💬 |
138 | Mannitol + pulmozyme (Tobrex (TN)) | 2件: Dornase alfa Dornase alfa, Mannitol | 2件: Mannitol
Mannitol
(Tobrex (TN)),
Dornase alfa
💬 | - | - | 1件: 299 299 💬 |
139 | Mannitol Inhalant Product (Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
(Tobrex (TN)) 💬 | - | - | 1件: 299 299 💬 |
140 | Mannitol inhalation powder (Tobrex (TN)) | 1件: Mannitol Mannitol | 1件: Mannitol
Mannitol
(Tobrex (TN)) 💬 | - | - | 1件: 299 299 💬 |
141 | Medication to suppress the immune system | - | - | - | - | 1件: 19 19 💬 |
142 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 💬 |
143 | MENINGOCOCCAL GROUP A OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 💬 |
144 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (beta197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 💬 |
145 | MENINGOCOCCAL GROUP W OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (ß197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 💬 |
146 | MENINGOCOCCAL GROUP Y OLIGOSACCHARIDES CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE C7 (Â197) M8 (CRM197) PROTEIN | 2件: Corynebacterium diphtheriae Corynebacterium diphtheriae (Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Diphtheria toxin mutant CRM197) | - | - | - | 1件: 11 11 💬 |
147 | Metformin 500 Mg Oral Tablet, up to 4 tablets a day | 1件: Metformin Metformin | 1件: Metformin
Metformin
💬 | 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
148 | Metronidazole (METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Metronidazole Topical Gel) | 1件: Metronidazole
Metronidazole
(METRONIDAZOLE TOPICAL CREAM) 💬 | - | - | 7件: 46 46, 51, 63, 94, 96, 97, 291 💬 |
149 | Metronidazole capsule 50 mg (METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Metronidazole Topical Gel) | 1件: Metronidazole
Metronidazole
(METRONIDAZOLE TOPICAL CREAM) 💬 | - | - | 1件: 97 97 💬 |
150 | Metronidazole Oral (METRONIDAZOLE TOPICAL CREAM) | 1件: Metronidazole Metronidazole (Metronidazole Topical Gel) | 1件: Metronidazole
Metronidazole
(METRONIDAZOLE TOPICAL CREAM) 💬 | - | - | 1件: 96 96 💬 |
151 | Midodrine or atomoxetine pill (Tomoxetine) | 2件: Atomoxetine Atomoxetine (Tomoxetine), Midodrine | 2件: Atomoxetine
Atomoxetine
(Tomoxetine),
Midodrine
💬 | 4件: ADRA1A ADRA1A, ADRA1B, ADRA1D, SLC6A2 💬 | 8件: AMPK signaling pathway AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Salivary secretion, Synaptic vesicle cycle, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 17 17 💬 |
152 | Minibody against CD8 conjugated to desferrioxamine labeled with zirconium Zr 89 | 1件: Deferoxamine Deferoxamine | 1件: Deferoxamine
Deferoxamine
💬 | - | - | 2件: 51 51, 53 💬 |
153 | Mobilization of stem cells to prepare for Leukapheresis | - | - | - | - | 1件: 96 96 💬 |
154 | Modified Oral Glucose Tolerance Test (50g 4-hours) | 1件: Dextrose, unspecified form Dextrose, unspecified form (50gm Glucose Tolerance Drink) | - | - | - | 1件: 299 299 💬 |
155 | Most recent vaccine to seasonal influenza | - | - | - | - | 1件: 13 13 💬 |
156 | MRA (Tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
157 | MRA(Tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
158 | MSC2430913A or ONO-4641 (to be used as synonyms) | - | - | - | - | 1件: 13 13 💬 |
159 | MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF | - | - | - | - | 1件: 2 2 💬 |
160 | Multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides) | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
161 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO | - | - | - | - | 1件: 11 11 💬 |
162 | N. MENINGITIDIS GROUP C (STRAIN C11) OLIGOSACCHARIDE CONJUGATED TO CORYNEBACTERIUM DIPHTHERIAE CRM197 ADSORBED ON ALUMINUM HYDROXIDE | 5件: Aluminium Aluminium, Aluminum hydroxide (Topcare Antacid Maximum Strength), Corynebacterium diphtheriae (Tetanus and Diphtheria Toxoids Adsorbed), Corynebacterium diphtheriae CRM197 protein (Diphtheria toxin mutant CRM197), Hydroxide ion | 1件: Aluminum hydroxide
Aluminum hydroxide
💬 | - | - | 1件: 11 11 💬 |
163 | Nanobody directed towards the human A1 domain of von Willebrand factor | 1件: Von Willebrand factor human Von Willebrand factor human | - | - | - | 1件: 64 64 💬 |
164 | Nebcin (tobramycin) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
165 | Nebcinal Tobi | - | - | - | - | 1件: 299 299 💬 |
166 | Nebulization tobramycin | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
167 | NEISSERIA MENINGITIDIS GROUP A POLYSACCHARIDE CONJUGATED WITH TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 💬 |
168 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETA | 1件: Triethylenetetramine Triethylenetetramine | - | - | - | 1件: 50 50 💬 |
169 | NEISSERIA MENINGITIDIS GROUP W-135 POLYSACCHARIDE CONJUGATED TO TETANUS TOXOID CARRIER PROTEIN | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 50 50 💬 |
170 | Onabotulinum Toxin A | - | - | - | - | 1件: 226 226 💬 |
171 | OPC-41061 (tolvaptan) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
172 | Open Label Topical Beremagene Geperpavec (B-VEC) | - | - | - | - | 1件: 36 36 💬 |
173 | Oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone | 2件: Mesalazine Mesalazine, Methylprednisolone | 2件: Mesalamine
Mesalamine
,
Methylprednisolone
💬 | 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 💬 |
174 | Oral Glucose Tolerance test (75g 2-hour) | 1件: Dextrose, unspecified form Dextrose, unspecified form (50gm Glucose Tolerance Drink) | - | - | - | 1件: 299 299 💬 |
175 | OSU 6162 similar to (-)-OSU 6162 | - | - | - | - | 1件: 6 6 💬 |
176 | OSU6162 similar to (-)-OSU 6162 | - | - | - | - | 2件: 6 6, 8 💬 |
177 | Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254measured as amount of total protein containing the PorA P1.4 | - | - | - | - | 1件: 11 11 💬 |
178 | Oxybutynin, tolterodine, solifenacin | 3件: Oxybutynin Oxybutynin, Solifenacin, Tolterodine | 3件: Oxybutynin
Oxybutynin
,
Tolterodine
,
Solifenacin
💬 | 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 53 53 💬 |
179 | Patients will be randomized to receive EHP-101 | - | - | - | - | 1件: 51 51 💬 |
180 | Pertussis toxoid | 1件: Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) | - | - | - | 1件: 46 46 💬 |
181 | PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE | 4件: Aluminium Aluminium, Aluminum hydroxide (Topcare Antacid Maximum Strength), Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated), Hydroxide ion | 1件: Aluminum hydroxide
Aluminum hydroxide
💬 | - | - | 1件: 46 46 💬 |
182 | Pharmacologic approaches to glycemic treatment | - | - | - | - | 1件: 298 298 💬 |
183 | Phentermine-Topiramate | 2件: Phentermine Phentermine, Topiramate | 2件: Topiramate
Topiramate
,
Phentermine
💬 | 41件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, MAOA, MAOB, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A, SLC6A2, SLC6A3, SLC6A4 💬 | 63件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Alcoholism, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arginine and proline metabolism, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, Drug metabolism - cytochrome P450, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, Glycine, serine and threonine metabolism, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Histidine metabolism, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Phenylalanine metabolism, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Synaptic vesicle cycle, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Tryptophan metabolism, Type II diabetes mellitus, Tyrosine metabolism, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 97 97 💬 |
184 | PLA + MTX switched to ABA+ MTX, DB | - | - | - | - | 1件: 46 46 💬 |
185 | PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED) CONJUGATED TO CRM197 CARRIER PROTEIN AND ADSORBED ON ALUMINIUM PHOSPHATE | 4件: Aluminium Aluminium, Aluminium phosphate, Corynebacterium diphtheriae CRM197 protein (Diphtheria toxin mutant CRM197), Phosphate ion | - | - | - | 1件: 46 46 💬 |
186 | Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin) | 1件: Activated charcoal Activated charcoal | - | - | - | 1件: 6 6 💬 |
187 | Positron Emission Tomography using [18 Fluorine]-altanserin ([18F]-altanserin) | - | - | - | - | 1件: 6 6 💬 |
188 | Previously referred to as MEDI2070 and AMG 139 | - | - | - | - | 2件: 96 96, 97 💬 |
189 | Previously referred to as MEDI2070 and AMG 139, AGN-151-598 | - | - | - | - | 1件: 96 96 💬 |
190 | PXT3003 Dose 2 (equivalent to twice Dose 1) | - | - | - | - | 1件: 10 10 💬 |
191 | QR-313 Gel for Topical (Cutaneous) Administration | - | - | - | - | 1件: 36 36 💬 |
192 | Rapamycin cream, topical, 0.5%, 1.0% w/w | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 158 158 💬 |
193 | RECOMBINANT HUMAN ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 FUSED TO THE FC FRAGMENT OF IGG1 | - | - | - | - | 1件: 166 166 💬 |
194 | Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class | - | - | - | - | 3件: 106 106, 107, 108 💬 |
195 | Recombinant human monoclonal antibody to Il-17 of the IgG1-k-class | - | - | - | - | 1件: 271 271 💬 |
196 | Recombinant human monoclonal antibody to inerleukin-1beta of the IgG1-K-class | - | - | - | - | 1件: 46 46 💬 |
197 | Recombinant human monoclonal antibody to interleukin-1beta of the IgG1-Kappa-class | - | - | - | - | 1件: 46 46 💬 |
198 | RECOMBINANT HUMAN SERUM ALBUMIN (HSA) FUSED TO HUMAN GROWTH HORMONE (HGH) | 2件: Albumin human Albumin human, Somatotropin | 1件: Albumin human
Albumin human
💬 | - | - | 1件: 78 78 💬 |
199 | Recombinant humanized monoclonal antibody omalizumab to IgE | 1件: Omalizumab Omalizumab | 1件: Omalizumab
Omalizumab
💬 | 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 299 299 💬 |
200 | Reduced Toxicity Ablative Regimen | - | - | - | - | 3件: 62 62, 65, 284 💬 |
201 | Response to anakinra associated with methotrexate | 2件: Anakinra Anakinra, Methotrexate | 2件: Methotrexate
Methotrexate
,
Anakinra
💬 | 4件: DHFR DHFR, DHFR2, IL1R1, IL1R2 💬 | 20件: Amoebiasis Amoebiasis, Antifolate resistance, Biosynthesis of cofactors, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Folate biosynthesis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, Metabolic pathways, NF-kappa B signaling pathway, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 1件: 46 46 💬 |
202 | Response to infliximab associated with methotrexate | 2件: Infliximab Infliximab, Methotrexate | 2件: Methotrexate
Methotrexate
,
Infliximab
💬 | 3件: DHFR DHFR, DHFR2, TNF 💬 | 71件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Biosynthesis of cofactors, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Folate biosynthesis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Metabolic pathways, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, One carbon pool by folate, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
203 | RhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 4件: 13 13, 46, 56, 96 💬 |
204 | RhumAb to Il-17A (IgG1-k-class) rhumAb to Il-17A (IgG1-k-class) | - | - | - | - | 1件: 96 96 💬 |
205 | RhumAb to IL-17A igG1-k-class | - | - | - | - | 1件: 13 13 💬 |
206 | RoActemra/Actemra (tocilizumab) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 107 107 💬 |
207 | RPC1063 (equivalent to ozanimod | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 💬 |
208 | RPC1063 (equivalent to ozanimod HCl) | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 💬 |
209 | RPC1063 equiv to ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 💬 |
210 | RPC1063 equiv. to ozanimod HCI | 1件: Ozanimod Ozanimod | 1件: Ozanimod
Ozanimod
💬 | 5件: S1PR1 S1PR1, S1PR2, S1PR3, S1PR4, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 96 96 💬 |
211 | SB2 (proposed biosimilar to infliximab) | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
212 | SB4 (proposed biosimilar to etanercept) | 1件: Etanercept Etanercept | 1件: Etanercept
Etanercept
💬 | 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
213 | SB5 (proposed biosimilar to adalimumab) | 1件: Adalimumab Adalimumab | 1件: Adalimumab
Adalimumab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 💬 |
214 | Sorafenib (as tosylate) | 1件: Sorafenib Sorafenib (Sorafenib Tosylate) | 1件: Sorafenib
Sorafenib
💬 | 8件: BRAF BRAF, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET 💬 | 89件: Acute myeloid leukemia Acute myeloid leukemia, Alcoholism, Alzheimer disease, Apelin signaling pathway, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bladder cancer, Breast cancer, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Chronic myeloid leukemia, Colorectal cancer, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Influenza A, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Long-term depression, Long-term potentiation, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Serotonergic synapse, Signaling pathways regulating pluripotency of stem cells, Sphingolipid signaling pathway, T cell receptor signaling pathway, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, VEGF signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway, mTOR signaling pathway 💬 | 1件: 34 34 💬 |
215 | Subcutaneous tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
216 | Subcutaneous tocilizumab 162mg/biweekly | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
217 | Suplatast tosilate | - | - | - | - | 1件: 226 226 💬 |
218 | Switch to Myfortic | 1件: Mycophenolic acid Mycophenolic acid | 1件: Mycophenolic acid
Mycophenolic acid
💬 | 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Nucleotide metabolism, Purine metabolism 💬 | 1件: 49 49 💬 |
219 | Takecab tablets + amoxicillin + clarithromycin (first-line eradication) Takecab tablets + amoxicillin + metronidazole (second-line eradication) (METRONIDAZOLE TOPICAL CREAM) | 3件: Amoxicillin Amoxicillin, Clarithromycin, Metronidazole (Metronidazole Topical Gel) | 4件: Amoxicillin
Amoxicillin
,
Clarithromycin
,
Metronidazole
(METRONIDAZOLE TOPICAL CREAM),
Amoxicillin
💬 | - | - | 1件: 63 63 💬 |
220 | Tedizolid (Torezolid) | 1件: Tedizolid Tedizolid (Torezolid) | 1件: Tedizolid
Tedizolid
(Torezolid) 💬 | - | - | 1件: 299 299 💬 |
221 | Tedizolid IV (Torezolid) | 1件: Tedizolid Tedizolid (Torezolid) | 1件: Tedizolid
Tedizolid
(Torezolid) 💬 | - | - | 1件: 299 299 💬 |
222 | Tedizolid PO (Torezolid) | 1件: Tedizolid Tedizolid (Torezolid) | 1件: Tedizolid
Tedizolid
(Torezolid) 💬 | - | - | 1件: 299 299 💬 |
223 | Temsirolimus (Torisel (TN)) | 1件: Temsirolimus Temsirolimus (Torisel) | 1件: Temsirolimus
Temsirolimus
(Torisel (TN)) 💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
224 | Temsirolimus Tablets (Torisel (TN)) | 1件: Temsirolimus Temsirolimus (Torisel) | 1件: Temsirolimus
Temsirolimus
(Torisel (TN)) 💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 13 13 💬 |
225 | Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleava | 2件: Polyethylene glycol Polyethylene glycol (Topcare ClearLax), Teriparatide | 2件: Polyethylene glycol 3350
Polyethylene glycol 3350
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
226 | Teriparatide conjugated to a multiarm polyethylene glycol carrier molecule through a cleavable linker | 2件: Polyethylene glycol Polyethylene glycol (Topcare ClearLax), Teriparatide | 2件: Polyethylene glycol 3350
Polyethylene glycol 3350
,
Teriparatide
💬 | 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 1件: 235 235 💬 |
227 | Tetanus diphtheria toxoid vaccine (Td) | 1件: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 💬 |
228 | Tetanus diphtheria toxoids vaccine | - | - | - | - | 1件: 13 13 💬 |
229 | Tetanus toxoid | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 4件: 13 13, 14, 46, 50 💬 |
230 | Tetanus toxoid (TT) containing vaccine (Td, Tdap) | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 💬 |
231 | Tetanus toxoid adsorbed | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 💬 |
232 | Tetanus toxoid adsorbed booster vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 💬 |
233 | Tetanus Toxoid Adsorbed Vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 46 46 💬 |
234 | Tetanus toxoid vaccine | 1件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated) | - | - | - | 1件: 13 13 💬 |
235 | Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed) | 3件: Clostridium tetani toxoid antigen (formaldehyde inactivated) Clostridium tetani toxoid antigen (formaldehyde inactivated), Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated), Pertussis vaccine (Diphtheria and Tetanus Toxoids With Pertussis Vaccine Adsorbed) | 1件: Pertussis vaccine
Pertussis vaccine
💬 | - | - | 1件: 46 46 💬 |
236 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA | - | - | - | - | 1件: 96 96 💬 |
237 | The investigational medicinal product (IMP) will be labeled as PF-04236921 106 mg/vial, Clonal SC lyophilized form, which is equivalent to PF-04236921 Powder for Injection, 106 mg/vial as described in the enclosed CTA. | - | - | - | - | 1件: 96 96 💬 |
238 | Time delay treatment of botulinum toxin | - | - | - | - | 1件: 149 149 💬 |
239 | TIP (Tobramycin inhalation powder) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
240 | TIS (Tobramycin Inhalation Solution) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
241 | TO | - | - | - | - | 1件: 6 6 💬 |
242 | To be confirmed | - | - | - | - | 3件: 46 46, 65, 97 💬 |
243 | To be determined | - | - | - | - | 2件: 96 96, 113 💬 |
244 | To be requested | - | - | - | - | 2件: 96 96, 97 💬 |
245 | TOBI | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
246 | TOBI (tobramycin) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
247 | TOBI 300 mg / 5 mL nebuliser solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
248 | TOBI 300 mg/5 ml Lösung für einen | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
249 | TOBI 300 mg/5 ml Lösung für einen Vernebler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
250 | TOBI 300 mg/5 ml Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
251 | TOBI 300 mg/5 ml solución para inhalación por nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
252 | TOBI 300 mg/5 ml, solution pour inhalation par nébuliseur | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
253 | TOBI 300mg/ 5ml solución para inhalación con nebulizador | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
254 | TOBI 300mg/5mL Nebuliser Solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
255 | Tobi 300mg/5ml Nebuliser solution. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
256 | Tobi 300mg/5ml Solución para inhalación por nebulizador. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
257 | Tobi Inhalant Product | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
258 | Tobi Nebcinal | - | - | - | - | 1件: 299 299 💬 |
259 | TOBI PODHALER | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
260 | TOBI PODHALER - 28 MG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER(ALU/ALU) 56 CAPSULE + 1 INALATORE | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
261 | TOBI Podhaler 28 mg Hartkapseln mit Pulver zur Inhalation | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
262 | TOBI Podhaler 28 mg inhalációs por, kemény kapszula | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
263 | TOBI PODHALER*448CPS 28MG+10IN | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
264 | TOBI*NEBUL 56F 1D 300MG/5ML | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
265 | TOBI® | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
266 | TOBI™ Podhaler™ 112 mg inhaled twice daily | - | - | - | - | 1件: 299 299 💬 |
267 | Tobramcyin | - | - | - | - | 1件: 299 299 💬 |
268 | TOBRAMICINA | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
269 | Tobramicina polvere inalatoria | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
270 | TOBRAMICINA SOLFATO | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
271 | Tobramicyn | - | - | - | - | 1件: 299 299 💬 |
272 | TOBRAMYCIN | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
273 | Tobramycin (Gernebcin®) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
274 | Tobramycin / Bramitob | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
275 | Tobramycin / TOBI | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
276 | Tobramycin 100 PARI | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
277 | Tobramycin dry powder | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
278 | Tobramycin for Inhalation | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
279 | Tobramycin Inhalation Powder | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
280 | Tobramycin Inhalation Powder (TIP) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
281 | Tobramycin Inhalation Powder TIP delivered by the T-326 Inhaler | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
282 | Tobramycin inhalation solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
283 | Tobramycin Inhalation Solution (TIS) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
284 | Tobramycin inhalation solution using a PARI LC® Plus nebulizer. | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
285 | Tobramycin injection 40mg/1ml | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
286 | Tobramycin nebulized nasally | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
287 | Tobramycin Powder | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
288 | Tobramycin Solution for Inhalation | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
289 | Tobramycin solution for inhalation (TOBI) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
290 | Tobramycin solution for inhalation 300 mg | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
291 | Tobramycin Steri-Neb 300 mg/5 ml, inhalation solution | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
292 | TOBRAMYCIN SULFATE | 2件: Sulfate ion Sulfate ion, Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
293 | Tobramycine | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
294 | Tobramycinum | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
295 | Tobrineb/Bramitob | - | - | - | - | 1件: 299 299 💬 |
296 | Tocilizmab | - | - | - | - | 1件: 46 46 💬 |
297 | Tocilizumab | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 21件: 2 2, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 💬 |
298 | Tocilizumab (Actemra or RoActemra) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
299 | Tocilizumab (Actemra) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
300 | Tocilizumab (Actemra®) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
301 | Tocilizumab (MRA-SC) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 40 40 💬 |
302 | Tocilizumab (TCZ) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 56 💬 |
303 | Tocilizumab + Glucocorticoids (GCs) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
304 | Tocilizumab + methotrexate(MTX) | 2件: Methotrexate Methotrexate, Tocilizumab | 2件: Methotrexate
Methotrexate
,
Tocilizumab
💬 | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
305 | Tocilizumab 162 mg | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
306 | Tocilizumab 162Mg/0.9Ml Autoinjector | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
307 | Tocilizumab 162mg/0.9ml jeringa SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
308 | Tocilizumab 162mg/0.9ml SC PFS SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
309 | Tocilizumab 162mg/0.9ml syringe SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
310 | Tocilizumab [RoActemra/Actemra] | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 4件: 46 46, 51, 107, 331 💬 |
311 | Tocilizumab [RoActemra] | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
312 | Tocilizumab and IV steroids combination | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
313 | Tocilizumab Infusion RoAcemtra (EU) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 266 266 💬 |
314 | Tocilizumab Injectable Product | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 11 11 💬 |
315 | Tocilizumab Injection | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 💬 |
316 | Tocilizumab Injection 8mg/kg | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
317 | Tocilizumab IV | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
318 | Tocilizumab plus methotrexate | 2件: Methotrexate Methotrexate, Tocilizumab | 2件: Methotrexate
Methotrexate
,
Tocilizumab
💬 | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
319 | Tocilizumab Prefilled Syringe | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 41 41, 46 💬 |
320 | Tocilizumab Roche | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬 |
321 | TOCILIZUMAB SC | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 41 41, 46, 107 💬 |
322 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
323 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
324 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 51 51 💬 |
325 | Tocilizumab treatment | 1件: Tocilizumab Tocilizumab | 1件: Tocilizumab
Tocilizumab
💬 | 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬 |
326 | Tocilizumab+Methotrexate(MTX) | 2件: Methotrexate Methotrexate, Tocilizumab | 2件: Methotrexate
Methotrexate
,
Tocilizumab
💬 | 3件: DHFR DHFR, DHFR2, IL6R 💬 | 17件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬 |
327 | Tocilizumab, Abatacept | 2件: Abatacept Abatacept, Tocilizumab | 2件: Tocilizumab
Tocilizumab
,
Abatacept
💬 | 3件: CD80 CD80, CD86, IL6R 💬 | 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬 |
328 | Tocilizumabum | - | - | - | - | 1件: 46 46 💬 |
329 | Tociluzumab | - | - | - | - | 1件: 65 65 💬 |
330 | Tocoferol | 1件: Tocopherol Tocopherol | 1件: Tocopherol
Tocopherol
💬 | - | - | 1件: 90 90 💬 |
331 | Tocopherol | 1件: Tocopherol Tocopherol | 1件: Tocopherol
Tocopherol
💬 | - | - | 5件: 13 13, 49, 206, 257, 298 💬 |
332 | Tocopherol (vit E) | 1件: Tocopherol Tocopherol | 1件: Tocopherol
Tocopherol
💬 | - | - | 1件: 257 257 💬 |
333 | Tocopherol acetate | 3件: Acetate Acetate, Tocopherol, alpha-Tocopherol acetate | 1件: Tocopherol
Tocopherol
💬 | - | - | 1件: 49 49 💬 |
334 | TOCOPHERYL ACETATE | 2件: Acetate Acetate, alpha-Tocopherol acetate | - | - | - | 1件: 206 206 💬 |
335 | Tocotrienol | 1件: Tocotrienol Tocotrienol | - | - | - | 3件: 21 21, 156, 299 💬 |
336 | Tocotrienols | - | - | - | - | 1件: 2 2 💬 |
337 | Tocovid Suprabio (HOV-12020) | - | - | - | - | 1件: 6 6 💬 |
338 | Toctino | 1件: Alitretinoin Alitretinoin (Toctino) | 1件: Alitretinoin
Alitretinoin
💬 | 5件: RARA RARA, RARB, RXRA, RXRB, RXRG 💬 | 19件: Acute myeloid leukemia Acute myeloid leukemia, Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 49 49 💬 |
339 | Toctino® | 1件: Alitretinoin Alitretinoin (Toctino) | 1件: Alitretinoin
Alitretinoin
💬 | 5件: RARA RARA, RARB, RXRA, RXRB, RXRG 💬 | 19件: Acute myeloid leukemia Acute myeloid leukemia, Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 1件: 49 49 💬 |
340 | TOFACINITIB | - | - | - | - | 1件: 97 97 💬 |
341 | Tofacitinb | - | - | - | - | 1件: 46 46 💬 |
342 | Tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 271, 300 💬 |
343 | Tofacitinib (CP-690,550) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 96 96 💬 |
344 | Tofacitinib (Xeljanz) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
345 | Tofacitinib (Xeljanz®) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
346 | Tofacitinib (Xeljanz®) 11mg Prolonged Release Tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
347 | Tofacitinib 10 mg | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 271 271 💬 |
348 | Tofacitinib 10 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
349 | Tofacitinib 2 mg | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 271 271 💬 |
350 | Tofacitinib 5 MG | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 4件: 11 11, 40, 46, 271 💬 |
351 | Tofacitinib 5 MG [Xeljanz] | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 50 💬 |
352 | Tofacitinib 5 mg twice daily | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
353 | Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 84 84 💬 |
354 | Tofacitinib 5mg po bid | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
355 | Tofacitinib citate (Phase III formulation) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
356 | TOFACITINIB CITRATE | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 5件: 46 46, 49, 97, 107, 271 💬 |
357 | Tofacitinib citrate (clinical trial image) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 💬 |
358 | Tofacitinib citrate (commercial image) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
359 | Tofacitinib citrate (Phase III formulation) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 💬 |
360 | Tofacitinib citrate (Proposed commercial formulation - debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 💬 |
361 | Tofacitinib citrate (Proposed commercial formulation debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
362 | Tofacitinib citrate (Proposed commercial formulation – debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 97 💬 |
363 | Tofacitinib citrate (Proposed commercial formulation- debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
364 | Tofacitinib citrate (Proposed commercialFormulation - debossed) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 97 97 💬 |
365 | TOFACITINIB CITRATE CP-690550 | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
366 | Tofacitinib citrate( Phase III formulation) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
367 | Tofacitinib or Baricitinib | 2件: Baricitinib Baricitinib, Tofacitinib | 2件: Tofacitinib
Tofacitinib
,
Baricitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
368 | Tofacitinib tablet | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 40 40 💬 |
369 | Tofacitinib with methotrexate | 2件: Methotrexate Methotrexate, Tofacitinib | 2件: Methotrexate
Methotrexate
,
Tofacitinib
💬 | 6件: DHFR DHFR, DHFR2, JAK1, JAK2, JAK3, TYK2 💬 | 42件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Antifolate resistance, Biosynthesis of cofactors, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Folate biosynthesis, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, Metabolic pathways, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, One carbon pool by folate, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
370 | Tofacitinib without methotrexate | 2件: Methotrexate Methotrexate, Tofacitinib | 2件: Methotrexate
Methotrexate
,
Tofacitinib
💬 | 6件: DHFR DHFR, DHFR2, JAK1, JAK2, JAK3, TYK2 💬 | 42件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Antifolate resistance, Biosynthesis of cofactors, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Folate biosynthesis, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, Metabolic pathways, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, One carbon pool by folate, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
371 | Tofacitinib XR | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 2件: 46 46, 271 💬 |
372 | Tofacitinib/baricitinib | 2件: Baricitinib Baricitinib, Tofacitinib | 2件: Tofacitinib
Tofacitinib
,
Baricitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 💬 |
373 | Tofacitinibe citrate | - | - | - | - | 1件: 107 107 💬 |
374 | Tofersen | 1件: Tofersen Tofersen | 1件: Tofersen
Tofersen
💬 | 1件: SOD1 SOD1 💬 | 8件: Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis, Chemical carcinogenesis - reactive oxygen species, Huntington disease, Longevity regulating pathway - multiple species, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Peroxisome, Prion disease 💬 | 1件: 2 2 💬 |
375 | TOL | - | - | - | - | 1件: 67 67 💬 |
376 | Tolcapon | 1件: Tolcapone Tolcapone | 1件: Tolcapone
Tolcapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 1件: 6 6 💬 |
377 | TOLCAPONE | 1件: Tolcapone Tolcapone | 1件: Tolcapone
Tolcapone
💬 | 1件: COMT COMT 💬 | 4件: Dopaminergic synapse Dopaminergic synapse, Metabolic pathways, Steroid hormone biosynthesis, Tyrosine metabolism 💬 | 3件: 6 6, 28, 127 💬 |
378 | TolDC | - | - | - | - | 1件: 46 46 💬 |
379 | Tolebrutinib | - | - | - | - | 2件: 11 11, 13 💬 |
380 | Tolebrutinib 120mg | - | - | - | - | 1件: 13 13 💬 |
381 | Tolebrutinib 60mg | - | - | - | - | 1件: 13 13 💬 |
382 | Tolebrutininb | - | - | - | - | 1件: 11 11 💬 |
383 | Tolerogenic dendritic cells | - | - | - | - | 2件: 46 46, 96 💬 |
384 | Tolerogenic dendritic cells (tolDC) | - | - | - | - | 1件: 13 13 💬 |
385 | Tolerogenic Dendritic cells loaded with myelin peptides | 1件: Myelin basic protein Myelin basic protein | - | - | - | 1件: 13 13 💬 |
386 | Tolerogenic Fibroblasts | - | - | - | - | 1件: 13 13 💬 |
387 | Tolfenamic Acid | 1件: Tolfenamic acid Tolfenamic acid | 1件: Tolfenamic acid
Tolfenamic acid
💬 | 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 5 5 💬 |
388 | Tolicizumab | - | - | - | - | 1件: 46 46 💬 |
389 | Tolicizumab Roche | - | - | - | - | 1件: 46 46 💬 |
390 | Tolperisone | 1件: Tolperisone Tolperisone | 1件: Tolperisone
Tolperisone
💬 | - | - | 1件: 13 13 💬 |
391 | Tolperisone HC1 | 1件: Tolperisone Tolperisone | 1件: Tolperisone
Tolperisone
💬 | - | - | 1件: 13 13 💬 |
392 | Tolperisone HCl | 1件: Tolperisone Tolperisone | 1件: Tolperisone
Tolperisone
💬 | - | - | 1件: 13 13 💬 |
393 | Tolpersan | - | - | - | - | 1件: 13 13 💬 |
394 | Tolposan | - | - | - | - | 1件: 13 13 💬 |
395 | Tolterodine | 1件: Tolterodine Tolterodine | 1件: Tolterodine
Tolterodine
💬 | 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 2件: 17 17, 53 💬 |
396 | Tolubuterol Hydrochloride | - | - | - | - | 1件: 6 6 💬 |
397 | TOLVAPTAN | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 4件: 67 67, 72, 86, 225 💬 |
398 | TOLVAPTAN (OPC-41061) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
399 | Tolvaptan (SAMSCA) | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 💬 |
400 | TOLVAPTAN 15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
401 | Tolvaptan 15 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
402 | Tolvaptan 15 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
403 | Tolvaptan 15mg | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
404 | TOLVAPTAN 30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
405 | Tolvaptan 30 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
406 | Tolvaptan 30 mg tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
407 | Tolvaptan 30mg | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
408 | TOLVAPTAN 45/15 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
409 | Tolvaptan 50mg Granules | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
410 | TOLVAPTAN 60/30 | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
411 | Tolvaptan 7.5 mg Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
412 | Tolvaptan in euvolemic hyponatremia | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 💬 |
413 | Tolvaptan IR | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
414 | Tolvaptan MR | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
415 | Tolvaptan Oral Tablet | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 72 72 💬 |
416 | Tolvaptan Suspension | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
417 | Tolvaptan Tablets | 1件: Tolvaptan Tolvaptan | 1件: Tolvaptan
Tolvaptan
💬 | 1件: AVPR2 AVPR2 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption 💬 | 1件: 67 67 💬 |
418 | Tominersen | - | - | - | - | 1件: 8 8 💬 |
419 | Tominersen 100 mg | - | - | - | - | 1件: 8 8 💬 |
420 | Tominersen 60 mg | - | - | - | - | 1件: 8 8 💬 |
421 | Top down treatment if patient at high risk | - | - | - | - | 2件: 96 96, 97 💬 |
422 | Top-down | - | - | - | - | 1件: 96 96 💬 |
423 | TOP1288 | - | - | - | - | 1件: 97 97 💬 |
424 | TOP1288 Rectal solution | - | - | - | - | 1件: 97 97 💬 |
425 | TOPAMAX | 1件: Topiramate Topiramate | 1件: Topiramate
Topiramate
💬 | 36件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 53件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 140 140 💬 |
426 | Topical 0.1% Sirolimus | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 278 278 💬 |
427 | Topical AmphiMatrix | - | - | - | - | 1件: 51 51 💬 |
428 | Topical AmphiMatrix with nitroglycerin (MQX-503) | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
429 | Topical beremagene geperpavec | - | - | - | - | 1件: 36 36 💬 |
430 | Topical BPM31510 3.0% Cream | - | - | - | - | 1件: 36 36 💬 |
431 | Topical calcipotriene 0.005% ointment | 1件: Calcipotriol Calcipotriol (Dovonex Solution - Top 50mcg/ml) | 1件: Calcipotriene
Calcipotriene
💬 | 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 51 51 💬 |
432 | Topical compound tripterygium | 1件: Tripterygium wilfordii whole Tripterygium wilfordii whole | - | - | - | 1件: 46 46 💬 |
433 | Topical garamycin cream | - | - | - | - | 2件: 35 35, 162 💬 |
434 | Topical infliximab | 1件: Infliximab Infliximab | 1件: Infliximab
Infliximab
💬 | 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 38 38, 39, 162 💬 |
435 | Topical opiod | - | - | - | - | 1件: 36 36 💬 |
436 | Topical organogel with nitroglycerin | 1件: Nitroglycerin Nitroglycerin | 1件: Nitroglycerin
Nitroglycerin
💬 | - | - | 1件: 51 51 💬 |
437 | Topical Pentoxifylline Gel (Vehicle +PTX) | 1件: Pentoxifylline Pentoxifylline | 1件: Pentoxifylline
Pentoxifylline
💬 | - | - | 1件: 56 56 💬 |
438 | Topical Preparation H arm | - | - | - | - | 1件: 13 13 💬 |
439 | Topical Rapamycin | 1件: Sirolimus Sirolimus | 1件: Sirolimus
Sirolimus
💬 | 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 1件: 157 157 💬 |
440 | Topical timolol maleate | 1件: Timolol Timolol | 2件: Timolol
Timolol
,
Timolol
💬 | 2件: ADRB1 ADRB1, ADRB2 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 227 227 💬 |
441 | Topical tripterygium gel | 1件: Tripterygium wilfordii whole Tripterygium wilfordii whole | - | - | - | 1件: 46 46 💬 |
442 | Topical Vehicle | - | - | - | - | 1件: 278 278 💬 |
443 | Topimarate | - | - | - | - | 1件: 144 144 💬 |
444 | Topimarato | - | - | - | - | 1件: 144 144 💬 |
445 | TOPIRAMATE | 1件: Topiramate Topiramate | 1件: Topiramate
Topiramate
💬 | 36件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 53件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 6件: 6 6, 97, 140, 144, 156, 193 💬 |
446 | Topiramate (drug) | 1件: Topiramate Topiramate | 1件: Topiramate
Topiramate
💬 | 36件: CA2 CA2, CA4, CACNA1C, CACNA1D, CACNA1F, CACNA1S, GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GRIA1, GRIA2, GRIA3, GRIA4, GRIK1, GRIK2, GRIK3, GRIK4, GRIK5, SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 | 53件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Arrhythmogenic right ventricular cardiomyopathy, Bile secretion, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cocaine addiction, Collecting duct acid secretion, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Gastric acid secretion, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Huntington disease, Hypertrophic cardiomyopathy, Insulin secretion, Long-term depression, Long-term potentiation, MAPK signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Nitrogen metabolism, Oxytocin signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Prion disease, Proximal tubule bicarbonate reclamation, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Spinocerebellar ataxia, Taste transduction, Tight junction, Transcriptional misregulation in cancer, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 💬 |
447 | Topotecan | 1件: Topotecan Topotecan | 1件: Topotecan
Topotecan
💬 | 1件: TOP1 TOP1 💬 | - | 1件: 25 25 💬 |
448 | Torvast | - | - | - | - | 1件: 13 13 💬 |
449 | TORVAST*10CPR 10MG | - | - | - | - | 1件: 13 13 💬 |
450 | Total Body Irradiation | - | - | - | - | 1件: 65 65 💬 |
451 | Total Body Irradiation (TBI) (Plan 1) | - | - | - | - | 2件: 60 60, 285 💬 |
452 | Total Dietary Replacement | - | - | - | - | 1件: 265 265 💬 |
453 | Total Glucosides Paeony Capsules | - | - | - | - | 1件: 271 271 💬 |
454 | TOTTIZIM - 1 G/10 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE PER USO ENDOVENOSO 1 FLACONCINO POLVERE + 1 FIALA SOLVENTE 10 ML | - | - | - | - | 1件: 299 299 💬 |
455 | Tovaxin | - | - | - | - | 1件: 13 13 💬 |
456 | Tovaxin Autologous T Cell Vaccine | - | - | - | - | 1件: 13 13 💬 |
457 | Toxicity, Pharmacokinetics | - | - | - | - | 1件: 34 34 💬 |
458 | TOZ | - | - | - | - | 1件: 6 6 💬 |
459 | TOZADENANT | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
460 | Tozadenant (SYN115) 120 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
461 | Tozadenant (SYN115) 180 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
462 | Tozadenant (SYN115) 240 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
463 | Tozadenant (SYN115) 60 mg BID | 1件: Tozadenant Tozadenant | 1件: Tozadenant
Tozadenant
💬 | 1件: ADORA2A ADORA2A 💬 | 7件: Alcoholism Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway 💬 | 1件: 6 6 💬 |
464 | Tozinameran | 1件: Tozinameran Tozinameran | 1件: Tozinameran
Tozinameran
💬 | - | - | 1件: 299 299 💬 |
465 | Treat to target | - | - | - | - | 1件: 46 46 💬 |
466 | Treatment with topical superpotent corticosteroid therapy | - | - | - | - | 1件: 162 162 💬 |
467 | Untreated to atorvastatin treatment | 1件: Atorvastatin Atorvastatin | 1件: Atorvastatin
Atorvastatin
💬 | 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 💬 |
468 | Urine samples taken to measure methotrexate and its major metabolite 7-OH-methotrexate level | 1件: Methotrexate Methotrexate | 1件: Methotrexate
Methotrexate
💬 | 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 💬 |
469 | Ursodeoxycholic acid combined with total glucosides of paeony | 1件: Ursodeoxycholic acid Ursodeoxycholic acid (BAMBOO SALT Eunganggo Jook Yeom Toothpaste) | 1件: Ursodiol
Ursodiol
💬 | 1件: NR1H4 NR1H4 💬 | 1件: Bile secretion Bile secretion 💬 | 1件: 93 93 💬 |
470 | VACCINO HAEMOPHILUS INFLUENZAE B CONIUGATO CON TOSSOIDETETANICO | - | - | - | - | 2件: 61 61, 62 💬 |
471 | Vantobra (tobramycin) | 1件: Tobramycin Tobramycin | 1件: Tobramycin
Tobramycin
💬 | - | - | 1件: 299 299 💬 |
472 | Vedolizumab, Ustekinumab, or Tofacitinib | 3件: Tofacitinib Tofacitinib, Ustekinumab, Vedolizumab | 3件: Vedolizumab
Vedolizumab
,
Ustekinumab
,
Tofacitinib
💬 | 9件: IL12A IL12A, IL12B, IL23A, ITGA4, ITGB7, JAK1, JAK2, JAK3, TYK2 💬 | 65件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, Arrhythmogenic right ventricular cardiomyopathy, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, ECM-receptor interaction, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Focal adhesion, Growth hormone synthesis, secretion and action, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Leukocyte transendothelial migration, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pertussis, Primary immunodeficiency, Prolactin signaling pathway, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Regulation of actin cytoskeleton, Rheumatoid arthritis, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Yersinia infection 💬 | 1件: 97 97 💬 |
473 | Vehicle of ADX-102 Topical Dermal Cream | - | - | - | - | 1件: 160 160 💬 |
474 | Wound topically irrigated with 500mg TXA | - | - | - | - | 1件: 70 70 💬 |
475 | XELJANZ (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: Tofacitinib
Tofacitinib
💬 | 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 65 65 💬 |
476 | ZX008 0.2 to 0.8 mg/kg/day | - | - | - | - | 2件: 140 140, 144 💬 |